Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has submitted to the European Medicines Agency (EMA) a protocol design for a Phase 3 trial and registration plan for its lead compound, CF101, in the treatment of rheumatoid...
Venaxis (NASDAQ:APPY), closely-held Strand Life Sciences of India and its U.S. subsidiary, Strand Genomics, have terminated a series of transactions between the companies. The termination affects an asset purchase...
Fourth quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) was $6.8-million, up 28% from $5.3-million a year ago. For all of 2015, revenue rose 28% to $25.2-million from $19.7-million for 2014. A net total of 258 TearLab...
The FDA has provided written feedback to Titan Pharmaceuticals (NASDAQ:TTNP) on the initial development plan for its proprietary ropinirole hydrochloride implant for Parkinson’s disease. Based on the FDA’s feedback on...
Pivotal Therapeutics (CSE:PVO; OTC PINK:PVTTF) currently is unable to repay $7.7-million of convertible notes, which came due March 4, 2016, and at least one noteholder has advised the company that it intends to...
WMUR Channel 9 in Manchester, NH has produced a segment about Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine, the first long-acting, subdermal buprenorphine implant for the maintenance treatment of opioid addiction...
Closely-held Soricimed Biopharma has announced positive top-line results from a Phase 1 open-label, dose escalation study of its first-in-class peptide, SOR-C13, in subjects with advanced solid tumor cancers. The...
Closely-held NovellusDx of Israel has appointed Heiner Dreismann and Dr. Charles Woler to the board. “The appointment of Drs. Dreismann and Woler, both venerated leaders in the biotech and pharma industries, with strong...
The FDA has extended its action date to consider approval of a NDA for Probuphine for the maintenance treatment of opioid addiction by the standard period to May 27 from Feb. 27. Following the Psychopharmacologic...
Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has reported revenue of $20-million for the final quarter of 2015, up 54% from $13-million in the year earlier quarter, and up 18% from the third quarter of 2015. Product...
The New York Times has published an article about addiction medicines that includes a segment about Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine, the first long-acting, subdermal buprenorphine implant for the...
Microbix Biosystems (TSX:MBX) expects a strong performance over the rest of the fiscal year based on indicated customer demand, leading the company to project record sales for the current fiscal year, ending Sept. 30...
Avivagen (TSX-V:VIV) has started a trial with UNAHCO at the University of the Philippines Los Banos to measure the benefits of OxC-beta livestock as a feed additive for broiler poultry. Trial design reflects a...
Fresenius Medical Care (FSE:FME; NYSE:FMS) has extended its exclusive licensing agreement with closely-held Interface Biologics for use of the Endexo technology in chronic dialysis systems to cover the acute dialysis...
Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone in total, with each study having enrolled nearly the same number of patients...
Dipexium Pharmaceuticals (NASDAQ:DPRX) said that Australia and New Zealand have issued new Locilex patents, with expiry dates in June 2033. The patents’ claims are directed to a novel formulation of Locilex, an...
Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has reported results of a Phase 2 clinical study of drug candidate, TT401, for the treatment of Type 2 diabetes. TT401 is a once-weekly administered oxyntomodulin analog...
Titan Pharmaceuticals’ (NASDAQ:TTNP) development and marketing partner, closely-held Braeburn Pharmaceuticals, and Knight Therapeutics (TSX:GUD) have entered into an agreement, giving Knight exclusive rights to...
Venaxis (NASDAQ:APPY) has entered into a series of agreements for a transaction with Strand Life Sciences Private Limited and its shareholders. Strand is a privately-held, global genomics and bioinformatics company...
Avivagen (TSX-V:VIV) has started a new broiler poultry trial with the institute of agro-food research and technology of Catalonia, Spain. The trial will test the efficacy of OxC-beta Livestock to enhance performance and...
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent titled, “A3 Adenosine Receptor Allosteric Modulators”. The composition of matter...
EyeGate Pharmaceuticals (NASDAQ:EYEG) has enrolled the first patient in a confirmatory Phase 3 clinical trial of its EGP-437 combination lead product in patients with non-infectious anterior uveitis, an inflammation of...